208 related articles for article (PubMed ID: 32024029)
1. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.
Liu Y; Wang S; Zhao X; Feng Y; Bormans G; Swinnen J; Oyen R; Huang G; Ni Y; Li Y
Diagnostics (Basel); 2020 Jan; 10(2):. PubMed ID: 32024029
[TBL] [Abstract][Full Text] [Related]
2. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
3. Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.
Liu Y; Yin T; Keyzer F; Feng Y; Chen F; Liu J; Song S; Yu J; Vandecaveye V; Swinnen J; Bormans G; Himmelreich U; Oyen R; Zhang J; Huang G; Ni Y
Oncotarget; 2017 Aug; 8(33):55204-55215. PubMed ID: 28903414
[TBL] [Abstract][Full Text] [Related]
4. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
5. Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI.
Liu Y; Guan Q; Kong X; De Keyzer F; Feng Y; Chen F; Yu J; Liu J; Song S; van Pelt J; Swinnen J; Bormans G; Oyen R; Wang S; Huang G; Ni Y; Li Y
Transl Oncol; 2020 Jan; 13(1):92-101. PubMed ID: 31810003
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
7. Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology.
Yin T; Liu Y; Peeters R; Feng Y; Yu J; Himmelreich U; Oyen R; Ni Y
Br J Cancer; 2017 Nov; 117(10):1529-1536. PubMed ID: 28910821
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
9. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
10. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
11. The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.
Dey S; Kumari S; Kalainayakan SP; Campbell J; Ghosh P; Zhou H; FitzGerald KE; Li M; Mason RP; Zhang L; Liu L
Oncotarget; 2018 Jan; 9(3):4090-4101. PubMed ID: 29423106
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Nathan P; Zweifel M; Padhani AR; Koh DM; Ng M; Collins DJ; Harris A; Carden C; Smythe J; Fisher N; Taylor NJ; Stirling JJ; Lu SP; Leach MO; Rustin GJ; Judson I
Clin Cancer Res; 2012 Jun; 18(12):3428-39. PubMed ID: 22645052
[TBL] [Abstract][Full Text] [Related]
14. Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy.
Gao M; Yao N; Huang D; Jiang C; Feng Y; Li Y; Lou B; Peng F; Sun Z; Ni Y; Zhang J
J Drug Target; 2015 Jun; 23(5):436-43. PubMed ID: 25582132
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.
Grisham R; Ky B; Tewari KS; Chaplin DJ; Walker J
Gynecol Oncol Res Pract; 2018; 5():1. PubMed ID: 29318022
[TBL] [Abstract][Full Text] [Related]
16. Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.
Li J; Chen F; Feng Y; Cona MM; Yu J; Verbruggen A; Zhang J; Oyen R; Ni Y
Transl Oncol; 2013 Feb; 6(1):42-50. PubMed ID: 23418616
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer.
Wang H; Marchal G; Ni Y
World J Radiol; 2011 Jan; 3(1):1-16. PubMed ID: 21286490
[TBL] [Abstract][Full Text] [Related]
18. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
20. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
